TherapeuticsMD (TXMD) EBT (2010 - 2026)

TherapeuticsMD (TXMD) has reported EBT for 17 consecutive years, with $164000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 69.91% year-over-year to $164000.0; the trailing twelve-month figure through Jun 2026 stood at -$263000.0 (up 56.67% YoY), and the FY2025 full-year result was -$653000.0, up 72.13% from the prior year.
• EBT improved to $164000.0 in Q2 2026 per TXMD's latest filing, from $103000.0 in the prior quarter.
• Across five years, EBT topped out at $48.5 million in Q4 2022 and bottomed at -$17.9 million in Q1 2022.
• Historically, EBT has averaged -$522055.6 across 5 years, with a median of -$738500.0 in 2024.
• The widest YoY moves for EBT: up 151.9% in 2025, down 798.8% in 2025.
• Over 5 years, EBT stood at $48.5 million in 2022, then slumped by 103.27% to -$1.6 million in 2023, then jumped by 105.24% to $83000.0 in 2024, then plunged by 798.8% to -$580000.0 in 2025, then soared by 128.28% to $164000.0 in 2026.
• According to Business Quant data, EBT over the past three periods registered $164000.0, $103000.0, and -$580000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.